This Phase II trial, sponsored by the National Cancer Institute, investigates the efficacy of neoadjuvant chemotherapy regimens in hormone receptor-poor/HER2-negative breast cancer, a segment with significant unmet medical need. The inclusion of carboplatin and bevacizumab may enhance pathologic complete response rates, potentially positioning these combinations as competitive options in the neoadjuvant setting. The results could influence treatment guidelines and market dynamics, particularly for therapies targeting this specific breast cancer subtype. Companies involved in breast cancer therapeutics should monitor outcomes closely for potential shifts in standard of care and consider implications for their own product pipelines.